SpectraScience, Inc. Reports Estimated Second Quarter Revenue of $310,000

SAN DIEGO, CA--(Marketwire - July 09, 2012) - SpectraScience, Inc. (PINKSHEETS: SCIE) (OTCQB: SCIE), a San Diego-based medical device company, today announced that it expects revenue of approximately $310,000 for the second quarter ended June 30, 2012. The Company also stated that it expects operating expenses in the quarter to be consistent with recent prior quarters.

“We began shipments of our WavSTAT4 Optical Biopsy System to PENTAX Europe just prior to the close of the quarter, which accounted for the revenue reported today,” said Michael Oliver, SpectraScience’s Chief Executive Officer. “We are preparing additional shipments under the initial purchase order, and beginning training programs and business development activities with PENTAX as part of the 5-year, 23-country distribution agreement signed last month.”

Conference Call

As previously announced, the Company will hold a conference call today at 4:30 p.m. Eastern (1:30 p.m. Pacific) to provide an update on its business and conduct a question and answer session with investors.

Individuals interested in listening to the conference call may do so by dialing 877- 407-0782, or for international callers 201-689-8567. The call is also being webcast, and can be accessed at www.InvestorCalendar.com.

A telephone replay will be available through September 9, 2012 by dialing 877-660-6853, or for international callers 201-612-7415, and entering the Account #: 286, and the Conference ID #: 396984. The webcast will be available on the Company’s Web site for 90 days following the completion of the call.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.